Phuturdex › Diseases › Myositis
Drugs in development · updated 30 October 2026
Myositis: drugs in development
As of 30 October 2026 there are 42 active clinical trials (recruiting or ongoing, phases I–III) on 42 drugs for myositis. 35 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Andecaliximab | II–III | 1 | NCT06508021 |
| DazukibartPF-06823859 | III | 1 | NCT05895786 |
| Telitacicept | II–III | 1 | NCT07355257 |
| CRT-402 | I–II | 1 | NCT07778446 |
| Descartes-08 | II | 1 | NCT07391605 |
| Empasiprubart IVARGX-117 | II | 1 | NCT06284954 |
| FilgotinibJyseleca® | II | 1 | NCT06285539 |
| FT839 | I–II | 1 | NCT07800871 |
| NKX019 | I–II | 1 | NCT06733935 |
| PF-08154225 | I–II | 1 | NCT07782450 |
| ADI-001 | I | 1 | NCT06375993 |
| ALLO-329 | I | 1 | NCT07085104 |
| AZD0120 | I | 1 | NCT07295847 |
| AZD5492 | I | 1 | NCT06916806 |
| BMS-986515 | I | 1 | NCT07115745 |
| BMS-986553 | I | 1 | NCT07873931 |
| CC-97540 | I | 1 | NCT05869955 |
| CNTY-101 | I | 1 | NCT06255028 |
| CTX112 | I | 1 | NCT06925542 |
| FT819 | I | 1 | NCT06308978 |
| GSK5926371 | I | 1 | NCT07371468 |
| ICG318 | I | 1 | NCT07715136 |
| KITE-363 | I | 1 | NCT07038447 |
| KYV-101 | I | 1 | NCT06152172 |
| OL-108 | I | 1 | NCT06980597 |
| OM336 | I | 1 | NCT07229144 |
| TI-0032-III | I | 1 | NCT07413341 |
| XmAb657 | I | 1 | NCT07284797 |
| CD19 | Early I | 2 | NCT06548607 |
| GC012F | Early I | 2 | NCT07086404 |
| CC312 | Early I | 1 | NCT06888960 |
| CD22 | Early I | 1 | NCT07174843 |
| MTS109 | Early I | 1 | NCT07526350 |
| UTAA91 | Early I | 1 | NCT06970951 |
| V001-BCMA | Early I | 1 | NCT07339540 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| CyclophosphamideCyclophosphamid, Cytoxan | II–III | 11 | NCT06154252 |
| FludarabineFludara, FLUDARABIN | II–III | 11 | NCT06154252 |
| NerandomilastBI 1015550, Jascayd® | III | 1 | NCT07789015 |
| NipocalimabM281, Imaavy® | II | 1 | NCT05379634 |
| UblituximabBriumvi® | II | 1 | NCT07103746 |
| TocilizumabTociluzumab, Avtozma | I | 2 | NCT05869955 |
| BendamustineBendamustin, Bedamustine | I | 1 | NCT06308978 |
Sorted by most advanced phase and number of active trials.
All 42 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Dermatomyositis 52 drugs
- Myositis ossificans 4 drugs
- Rheumatoid arthritis 130 drugs
- Systemic scleroderma 77 drugs
- Polymyositis 36 drugs
- Inclusion body myositis 3 drugs
- Heterotopic ossification 3 drugs
- Psoriatic arthritis 48 drugs
- Systemic lupus erythematosus 178 drugs
- Antiphospholipid syndrome 6 drugs
- Behcet Syndrome 11 drugs
- Autoimmune thrombocytopenic purpura 53 drugs
Broader categories
- Nervous System Diseases 39 drugs
- Neuromuscular disease 14 drugs
- Musculoskeletal disorder 22 drugs
- Muscular disease 12 drugs
- Skin and connective tissue diseases 3 drugs
- Immune System Diseases 54 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D009220 “Myositis”.